News - Astellas Pharma, Vibativ


Current filters:

Astellas PharmaVibativ

Popular Filters

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane


UK-based Clinigen Group (LSE: CLIN ) and Theravance (Nasdaq: THRX) of the USA have entered into an exclusive…

Antibiotics and Infectious diseasesAstellas PharmaceftolozaneClinigen GroupCubist PharmaceuticalsEuropeGlobalLicensingPharmaceuticalTheravanceVibativ

Astellas pulls out of deal with Theravance


Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA


The European Commission has granted marketing authorization for Japanese drug major Astellas’ (TYO:…

Antibiotics and Infectious diseasesAstellas PharmaEuropePharmaceuticalRegulationTheravanceVibativ

Back to top